<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080275</url>
  </required_header>
  <id_info>
    <org_study_id>019-02-03-CR</org_study_id>
    <secondary_id>OCEANS</secondary_id>
    <nct_id>NCT00080275</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety &amp; Efficacy of a Combination of Niacin ER &amp; Simvastatin in Patients With Dyslipidemia (OCEANS)</brief_title>
  <official_title>An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kos Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this 24 week study is to compare the effectiveness and safety of different&#xD;
      doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood&#xD;
      (dyslipidemia).&#xD;
&#xD;
      At least 600 subjects with a similar medical condition will take part in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      To evaluate the safety and efficacy of the combination product niacin ER and simvastatin (NS)&#xD;
      in patients with primary type II dyslipidemia and to descriptively compare flushing rates&#xD;
      between two Titration Schedules for NS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>600</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin Extended-Release and simvastatin Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has primary Type II hyperlipidemia or mixed dyslipidemia.&#xD;
&#xD;
          -  If the patient is currently taking a lipid modifying medication other than Zocor &amp;&#xD;
             he/she is willing to discontinue this medication&#xD;
&#xD;
          -  LDL-C levels and/or non HDL-C levels above normal.&#xD;
&#xD;
          -  Reasonable compliance with a standard cholesterol-lowering diet for a minimum of 4&#xD;
             weeks prior to screening and for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has an allergy, hypersensitivity, or intolerance to niacin, statins, or their&#xD;
             derivatives.&#xD;
&#xD;
          -  HbA1c â‰¥ 9% in diabetic patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>March 25, 2004</study_first_submitted>
  <study_first_submitted_qc>March 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2004</study_first_posted>
  <last_update_submitted>October 31, 2006</last_update_submitted>
  <last_update_submitted_qc>October 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2006</last_update_posted>
  <keyword>Niacin</keyword>
  <keyword>Statin</keyword>
  <keyword>Zocor</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Stroke</keyword>
  <keyword>High-Density Lipoprotein Cholesterol</keyword>
  <keyword>Low-Density Lipoprotein Cholesterol</keyword>
  <keyword>Lipoprotein</keyword>
  <keyword>Lipid</keyword>
  <keyword>Niacin ER/simvastatin</keyword>
  <keyword>Total Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

